Management of Premature Ventricular Contractions (PVCs)

Initial Pharmacologic Approach

The American College of Cardiology recommends beta-blockers or non-dihydropyridine calcium channel blockers as the first-line medications for managing symptomatic PVCs, even in patients with a baseline heart rate of 60 bpm 1, 2
Metoprolol or atenolol are the preferred beta-blockers for PVC suppression, with atenolol demonstrating significant reduction in both symptom frequency and PVC count in randomized controlled trials 1
The American College of Cardiology suggests starting with low doses of beta-blockers despite the baseline heart rate of 60 bpm, as the goal is arrhythmia suppression rather than rate control 1
Non-dihydropyridine calcium channel blockers, such as verapamil or diltiazem, are equally effective first-line options when beta-blockers are contraindicated or not tolerated 1, 2

The European Heart Journal suggests considering amiodarone when beta-blockers and calcium channel blockers are ineffective, not tolerated, or contraindicated 3, 2
Amiodarone has minimal negative inotropic effects compared to other antiarrhythmics, making it safer in patients with borderline bradycardia 2
The American College of Cardiology recommends avoiding Class I antiarrhythmic medications, such as flecainide and propafenone, in post-MI patients or those with reduced LVEF due to increased mortality risk 4

The American College of Cardiology and the European Heart Journal recommend catheter ablation as the definitive treatment for drug-resistant symptomatic PVCs despite trials of beta-blockers and calcium channel blockers 1, 3
Catheter ablation is also recommended for patients with PVC burden >15%, which carries a risk of PVC-induced cardiomyopathy 2, 4
The European Heart Journal suggests considering catheter ablation in patients who do not wish long-term drug therapy 3, 4
Ablation achieves 90-93% acute procedural success rates and reduces PVC burden from 17-20% to approximately 0.6-0.8% 4

The American College of Cardiology recommends obtaining 24-hour Holter monitoring to quantify exact PVC burden, as this determines treatment intensity 2, 4
PVC burden ≥24% is independently associated with cardiomyopathy, but even burdens >10% can cause ventricular dysfunction 4
The American College of Cardiology suggests performing echocardiography to assess left ventricular function and rule out structural heart disease 4

The American College of Cardiology recommends not assuming all dropped beats are PVCs without Holter confirmation, as conduction abnormalities may coexist 5
The American College of Cardiology suggests not withholding beta-blockers solely due to heart rate of 60 bpm if PVCs are symptomatic or frequent, as the therapeutic benefit outweighs bradycardia concerns in most cases 1
The American College of Cardiology recommends not using Class I antiarrhythmics as first-line therapy due to proarrhythmic risk and lack of mortality benefit 4
The American College of Cardiology suggests not delaying ablation referral in patients with PVC burden >15% and declining LV function, as early intervention prevents irreversible cardiomyopathy 4

The American College of Cardiology recommends eliminating aggravating factors, including excessive caffeine, alcohol, and sympathomimetic agents, as initial management 1, 4
This approach alone may be sufficient for mild symptoms in patients with structurally normal hearts 1